EMA/85751/2013

European Medicines Agency decision

P/0056/2013

of 25 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for oritavancin (diphosphate) (EMEA-001270-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0056/2013

of 25 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for oritavancin (diphosphate) (EMEA-001270-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by The Medicines Company on 12 March 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 February 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for oritavancin (diphosphate), powder for solution for injection, age-appropriate dosage form for parenteral use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for oritavancin (diphosphate), powder for solution for injection, age-appropriate dosage form for parenteral use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 3

This decision is addressed to The Medicines Company, 8 Sylvan Way, NJ 07054 – Parsippany, United States.

Done at London, 25 March 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/754798/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001270-PIP01-12

Scope of the application

Active substance(s):

Oritavancin (diphosphate)

Condition(s):

Treatment of skin and subcutaneous tissue bacterial infections

Pharmaceutical form(s):

Powder for solution for injection

Age-appropriate dosage form for parenteral use

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

The Medicines Company

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, The Medicines Company submitted for agreement to the European Medicines Agency on 12 March 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 April 2012.

Supplementary information was provided by the applicant on 16 November 2012. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 8 February 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of skin and subcutaneous tissue bacterial infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated skin and subcutaneous tissue infections, caused by susceptible isolates of gram-positive microorganisms.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for injection.

Age-appropriate dosage form for parenteral use.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	**Measure 1:** Age-appropriate dosage form for parenteral use for the paediatric population from birth to 12 months of age
Non-clinical	0	Not applicable.
Clinical	2	**Measure 2:** Open label, dose finding trial to evaluate PK, safety and tolerability of oritavancin single dose infusion in children from birth to less than 18 years of age with diagnosed or suspected bacterial infections receiving antibiotic therapy. **Measure 3:** Evaluator-blind, randomised, multicentre, single dose, active controlled trial to evaluate safety and tolerability of oritavancin in children from birth to less than 18 years of age with skin and subcutaneous tissue bacterial infections, suspected to be caused by gram-positive pathogens.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes